BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-on-one meetings at the following upcoming conferences:
| BofA Securities 2022 Healthcare Conference | |
| Date: | Tuesday, May 10 |
| Time: | 3:40 pm ET / 12:40 pm PT |
| Presentation: | Click Here |
| A replay of the presentation will be available on the investors portion of the company’s website. | |
| H.C. Wainwright Global Investment Conference | |
| Date: | May 23-26 |
| Time: | On demand presentation |
| Register: | Click Here |
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an oral LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an oral galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an oral galectin-3 inhibitor (GB1211) in a planned phase 2 trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO | |
| Jon Freve, CFO | |
| +45 70 70 52 10 | |
| Investors/US | Media/EU |
| Ashley R. Robinson | Sandya von der Weid |
| arr@lifesciadvisors.com | svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
